Navegando por Assunto COVID-19 - Vaccine

Ir para: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ou entre com as primeiras letras:  
Mostrando resultados 1 a 16 de 16
Data do documentoTítuloAutor(es)
2020Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated?Reiter, Paul L.; Pennell, Michael L.; Katz, Mira L.
Set-2020Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopesGalili, Uri
Set-2020Approaches and challenges in SARS-CoV-2 vaccine developmentDagotto, Gabriel; Yu, Jingyou; Barouch, Dan H.
Jun-2020COVID-19 vaccine development pipeline gears upMullard, Asher
Jun-2020COVID-19 vaccines for all?Usher, Ann Danaiya
2020COVID-19 vaccines in pregnancyCraig, Amanda M.; Hughes, Brenna L.; Swamy, Geeta K.
2021Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveriesMarian, Ali J.
Mar-2020Ensuring global access to COVID-19 vaccinesYamey, Gavin; Schäferhoff, Marco; Hatchett, Richard; Pate, Muhammad; Zhao, Feng; McDade, Kaci Kennedy
Out-2020Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemicDetoc, Maëlle; Bruel, Sébastien; Frappe, Paul; Tardy, Bernard; Botelho-Nevers, Elisabeth; Gagneux-Brunon, Amandine
2020Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19Sempowski, Gregory D.; Saunders, Kevin O.; Acharya, Priyamvada; Wiehe, Kevin J.; Haynes, Barton F.
Jan-2021Prevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccineBakadia, Bianza Moise; He, Feng; Souho, Tiatou; Lamboni, Lallepak; Ullah, Muhammad Wajid; Boni, Biaou Ode; Ahmed, Abeer Ahmed Qaed; Mukole, Biampata Mutu; Yang, Guang
Abr-2020Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the statusEl-Aziz, Tarek Mohamed Abd; Stockand, James D.
Mai-2020Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialZhu, Feng-Cai; Li, Yu-Hua; Guan, Xu-Hua; Hou, Li-Hua; Wang, Wen-Juan; Li, Jing-Xin; Wu, Shi-Po; Wang, Bu-Sen; Wang, Zhao; Wang, Lei; Jia, Si-Yue; Jiang, Hu-Dachuan; Wang, Ling; Jiang, Tao; Hu, Yi; Gou, Jin-Bo; Xu, Sha-Bei; Xu, Jun-Jie; Wang, Xue-Wen; Wang, Wei; Chen, Wei
Out-2020SARS-CoV-2 vaccine development: current statusPoland, Gregory A.; Ovsyannikova, Inna G.; Crooke, Stephen N.; Kennedy, Richard B.
2020Use of adenovirus type-5 vectored vaccines: a cautionary taleBuchbinder, Susan P.; McElrath, M. Juliana; Dieffenbach, Carl; Corey, Lawrence
2020What defines an efficacious COVID-19 vaccine? a review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2Hodgson, Susanne H.; Mansatta, Kushal; Mallett, Garry; Harris, Victoria; Emary, Katherine R. W.; Pollard, Andrew J.